

Gundu Hr Rao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3685043/publications.pdf>

Version: 2024-02-01

78
papers

2,061
citations

201385

27
h-index

253896

43
g-index

78
all docs

78
docs citations

78
times ranked

1395
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of plasma glow for surface-engineering biomolecules to enhance bloodcompatibility of Dacron and PTFE vascular prosthesis. <i>Biomaterials</i> , 2000, 21, 699-712.	5.7	158
2	Evaluation of Modified Alginate-Chitosan-Polyethylene Glycol Microcapsules for Cell Encapsulation. <i>Artificial Organs</i> , 1999, 23, 894-903.	1.0	115
3	Polymorphisms in the Fatty Acid-Binding Protein 2 and Apolipoprotein C-III Genes Are Associated with the Metabolic Syndrome and Dyslipidemia in a South Indian Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1705-1711.	1.8	100
4	Influence of epinephrine on the aggregation response of aspirin-treated platelets. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1980, 5, 45-58.	1.2	83
5	Effect of docosahexaenoic acid (DHA) on arachidonic acid metabolism and platelet function. <i>Biochemical and Biophysical Research Communications</i> , 1983, 117, 549-555.	1.0	81
6	Arachidonate-induced platelet aggregation in the dog. <i>Thrombosis Research</i> , 1979, 14, 147-154.	0.8	72
7	Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interactions. <i>Thrombosis Research</i> , 1986, 44, 65-74.	0.8	71
8	Measurement of ionized calcium in blood platelets with a new generation calcium indicator. <i>Biochemical and Biophysical Research Communications</i> , 1985, 132, 652-657.	1.0	69
9	Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase-deficient platelets. <i>American Journal of Hematology</i> , 1981, 11, 355-366.	2.0	55
10	Vessel wall arachidonate metabolism after angioplasty: Possible mediators of postangioplasty vasospasm. <i>American Journal of Cardiology</i> , 1983, 51, 1441-1445.	0.7	53
11	Delivery of LMW Heparin via Surface Coated Chitosan/peg-Alginate Microspheres Prevents Thrombosis. <i>Drug Delivery</i> , 2002, 9, 87-96.	2.5	49
12	Measurement of ionized calcium in normal human blood platelets. <i>Analytical Biochemistry</i> , 1988, 169, 400-404.	1.1	44
13	Chronomics*â€: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutraceuticals and beyond. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003, 3, 223-260.	0.5	44
14	Modification of human platelet response to sodium arachidonate by membrane modulation. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1981, 6, 75-90.	1.2	40
15	The role of iron in prostaglandin synthesis: Ferrous iron mediated oxidation of arachidonic acid. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1978, 1, 55-70.	1.2	37
16	Vitamin E inhibits the release of calcium from a platelet membrane fraction in vitro. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1979, 2, 203-216.	1.2	37
17	Platelet aggregation independent of adp release or prostaglandin synthesis in patients with Hermansky-Pudlak syndrome. <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> , 1981, 6, 459-472.	1.2	36
18	Labile Aggregation Stimulating Substance (LASS): the Factor from Storage Pool Deficient Platelets Correcting Defective Aggregation and Release of Aspirin Treated Normal Platelets. <i>British Journal of Haematology</i> , 1975, 29, 657-665.	1.2	35

#	ARTICLE	IF	CITATIONS
19	The influence of epinephrine on prostacyclin (PGI ₂) induced dissociation of adp aggregated platelets. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1980, 4, 385-397.	1.2	33
20	Influence of trifluoperazine on platelet aggregation and disaggregation. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1980, 5, 221-234.	1.2	33
21	Rapid separation of platelet nucleotides by reversed-phase, isocratic, high-performance liquid chromatography with a radially compressed column. Biomedical Applications, 1981, 226, 466-470.	1.7	32
22	Glutathione levels in human platelets display a circadian rhythm in vitro. Thrombosis Research, 1985, 40, 823-831.	0.8	31
23	Aflatoxin detection by high-speed liquid chromatography and mass spectrometry. Journal of Chromatography A, 1973, 84, 402-406.	1.8	30
24	Development of polylactide microspheres for protein encapsulation and delivery. Journal of Applied Polymer Science, 2002, 86, 1285-1295.	1.3	30
25	Effects of 2,2â€²-dipyridyl and related compounds on platelet prostaglandin synthesis and platelet function. Biochimica Et Biophysica Acta - General Subjects, 1980, 628, 468-479.	1.1	29
26	Disaggregation and reaggregation of â€œirreversiblyâ€™ aggregated platelets: A method for more complete evaluation of anti-platelet drugs. Agents and Actions, 1985, 16, 425-434.	0.7	29
27	Interpretation of Benefit-Risk of Enoxaparin as Comparator in the RECORD Program: Rivaroxaban Oral Tablets (10 milligrams) for Use in Prophylaxis in Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Hip or Knee Replacement Surgery. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 389-394.	0.7	28
28	Rapid return of cyclo-oxygenase active platelets in dogs after a single oral dose of aspirin. Prostaglandins, 1981, 22, 761-772.	1.2	27
29	Role of arachidonic acid metabolism in human platelet activation and irreversible aggregation. American Journal of Hematology, 1985, 19, 339-347.	2.0	27
30	Influence of nitric oxide on agonist-mediated calcium mobilization in platelets. Biochemical Medicine and Metabolic Biology, 1990, 43, 271-275.	0.7	27
31	Effect of low doses of ethanol on platelet function in long-life abstainers and moderate-wine drinkers. Life Sciences, 2003, 73, 1557-1566.	2.0	27
32	Diphenylamine: An unusual antioxidant. Free Radical Biology and Medicine, 1993, 14, 381-387.	1.3	25
33	Development of Poly(Lactic Acid)/Chitosan Co-Matrix Microspheres: Controlled Release of Taxol-Heparin for Preventing Restenosis. Drug Delivery, 2001, 8, 77-86.	2.5	24
34	Risk Factors for Heart Attack, Stroke, and Venous Thrombosis Associated With Hormonal Contraceptive Use. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 323-331.	0.7	24
35	Ferrous iron mediated oxidation of arachidonic acid: studies employing nitroblue tetrazolium (NBT). Prostaglandins, Leukotrienes and Essential Fatty Acids, 1978, 1, 304-317.	1.2	23
36	The influence of glutathione depleting agents on human platelet function. Thrombosis Research, 1989, 53, 457-465.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Role of glutathione and glutathione peroxidase in human platelet arachidonic acid metabolism. Prostaglandins, 1989, 38, 21-32.	1.2	21
38	The Development of Porous Alginate/Elastin/PEG Composite Matrix for Cardiovascular Engineering. Journal of Biomaterials Applications, 2003, 17, 287-301.	1.2	20
39	Inhibition of ferrous iron induced oxidation of arachidonic acid by indomethacin. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1979, 2, 97-108.	1.2	19
40	Intracerebral Hemorrhage. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 652-662.	0.7	19
41	Influence of pH on the prostacyclin (PGI ₂) mediated inhibition of platelet function. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1980, 4, 263-273.	1.2	18
42	Low dose aspirin, platelet function and prostaglandin synthesis: Influence of epinephrine and alpha adrenergic blockade. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1981, 6, 485-494.	1.2	18
43	Smoking and platelet labile aggregation stimulating substance (LASS) synthesizing activity. Thrombosis Research, 1976, 9, 661-668.	0.8	16
44	Influence of a calcium dependent protease inhibitor on platelet activation and secretion. Thrombosis Research, 1987, 47, 625-637.	0.8	16
45	Rapid separation of nucleotides from granulocytes by isocratic, reversed-phase high-performance liquid chromatography. Biomedical Applications, 1982, 229, 205-210.	1.7	15
46	Platelet Function in the Racing Thoroughbred: Implication for Exercise-Induced Pulmonary Hemorrhage. Veterinary Clinical Pathology, 1990, 19, 35-39.	0.3	15
47	Vascular disease: obesity and excess weight as modulators of risk. Expert Review of Cardiovascular Therapy, 2011, 9, 525-534.	0.6	15
48	Influence of esterase inhibitors on platelet aggregation and release induced by phorbol myristate acetate. Biochemical Pharmacology, 1975, 24, 293-295.	2.0	14
49	Aspirin Resistance: Does It Exist?. Seminars in Thrombosis and Hemostasis, 2007, 33, 210-214.	1.5	13
50	Irreversible platelet aggregation does not depend on lipoxygenase metabolites. Biochemical and Biophysical Research Communications, 1985, 131, 50-57.	1.0	12
51	Alpha tocopherol quinone (α TQ): A potent inhibitor of platelet function. Progress in Lipid Research, 1981, 20, 549-552.	5.3	11
52	Human Platelet Activation Is Inhibited by the Occupancy of Glycoprotein IIb/IIIa Receptor. Archives of Biochemistry and Biophysics, 1996, 333, 407-413.	1.4	11
53	Influence of calmodulin antagonist (stelazine) on agonist-induced calcium mobilization and platelet activation. Biochemical and Biophysical Research Communications, 1987, 148, 768-775.	1.0	10
54	Antioxidants, atherosclerosis and thrombosis. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 54, 155-166.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Simple method for the separation of monohydroxy fatty acid metabolites of arachidonate metabolism. Biomedical Applications, 1982, 232, 176-179.	1.7	8
56	Platelet hypersensitivity induced by 1-chloro-2,4-dinitrobenzene, hydroperoxides and inhibition of lipoxygenase. Thrombosis Research, 1989, 53, 447-455.	0.8	8
57	Reduction of heme by lipid peroxides and its potential relevance to understanding control of cyclo-oxygenase activity. Progress in Lipid Research, 1981, 20, 299-301.	5.3	7
58	Influence of heparins on inositol 1,4,5-trisphosphate-induced calcium mobilization in permeabilized human platelets. Biochemical Medicine and Metabolic Biology, 1991, 45, 171-180.	0.7	7
59	Differential response of human and bovine platelets to bovine von Willebrand factor and vascular subendothelium. Platelets, 2001, 12, 150-155.	1.1	7
60	The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 5-7.	0.7	7
61	Inhibition of platelet aggregation by novel triphenylethylene analogs. Thrombosis Research, 1986, 44, 527-538.	0.8	6
62	The influence of metabolites on the assay of platelet serotonin. Thrombosis Research, 1977, 10, 791-802.	0.8	5
63	Arachidonic acid metabolism in thrombocytes and vascular tissues of turkeys. Prostaglandins, 1985, 30, 999-1017.	1.2	5
64	INFLUENCE OF IONIZED CALCIUM ON THROMBIN-INDUCED DOWN REGULATION OF GPIb/IX RECEPTORS ON HUMAN PLATELETS. Thrombosis Research, 1997, 85, 23-31.	0.8	5
65	Need for a Point-of-Care Assay for Monitoring Antiplatelet and Antithrombotic Therapies. Stroke, 2009, 40, 2271-2272.	1.0	5
66	Rapid separation of tumor-promoting agents, phorbol and phorbol myristate acetate (12-O-tetradecanoylphorbol-13-acetate) by high-pressure liquid chromatography. Journal of Chromatography A, 1974, 96, 151-154.	1.8	4
67	Preparation, separation and characterization of vitamin E quinone. Journal of Chromatography A, 1980, 196, 506-511.	1.8	4
68	Differential effects of putative inhibitors on cytosolic and membrane associated platelet lipoxygenase. Prostaglandins, Leukotrienes, and Medicine, 1987, 26, 281-290.	0.8	4
69	An improved method for measuring endogenous serotonin in platelets of patients with Hermansky-Pudlak syndrome. Thrombosis Research, 1988, 51, 225-227.	0.8	4
70	Preparation of Surface-Engineered Elastin/Lamin Nerve Guide Tubes of Poly(Lactic Acid)/Poly(Ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	4
71	Aspirin resistance: A fact or a myth?. Experimental and Clinical Cardiology, 2005, 10, 17-20.	1.3	4
72	Influence of phospholipase A2 on human blood platelet alpha adrenergic receptor function. Thrombosis Research, 1989, 53, 427-434.	0.8	3

#	ARTICLE	IF	CITATIONS
73	Influence of calcium antagonists on thrombin-induced calcium mobilization and platelet-vessel wall interactions. <i>Biochemical Medicine and Metabolic Biology</i> , 1992, 47, 226-231.	0.7	3
74	AGGREGATED-DISAGGREGATED, REFRACTORY PLATELETS RETAIN SENSITIVITY TO RISTOCETIN. <i>Thrombosis Research</i> , 1996, 84, 253-266.	0.8	3
75	Changes in Pericardial Calcification Due to Antiplatelet Agents: In Vitro Studies. <i>Artificial Organs</i> , 1998, 22, 666-671.	1.0	3
76	Potential Thrombogenic Complications With the Use of Recombinant Activated Factor VII in Combat Trauma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007, 13, 121-123.	0.7	2
77	Arachidonic Acid Oxidation and Platelet Function. , 1990, , 779-789.		1
78	Coronavirus Disease and Acute Vascular Events. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092909.	0.7	0